ceftolozane 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
antibiotics, cefalosporanic acid derivatives 4922 689293-68-3

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • FR-264205
  • FR 264205
  • ceftolozane
  • ceftolozane sulfate
  • zerbaxa
  • CXA-101
  • FR264205
Ceftolozane belongs to the cephalosporin class of antibacterial drugs. The bactericidal action of ceftolozane results from inhibition of cell wall biosynthesis, and is mediated through binding to penicillin-binding proteins (PBPs). Ceftolozane is an inhibitor of PBPs of P. aeruginosa (e.g., PBP1b, PBP1c, and PBP3) and E. coli (e.g., PBP3).
  • Molecular weight: 667.70
  • Formula: C23H31N12O8S2
  • CLOGP: -9.85
  • LIPINSKI: 3
  • HAC: 20
  • HDO: 8
  • TPSA: 299.38
  • ALOGS: -4.03
  • ROTB: 12

  • Status: ONP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
3 g P

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 3 Hosey CM, Chan R, Benet LZ
Vd (Volume of distribution) 0.17 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 1.16 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.81 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 2.58 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Dec. 19, 2014 FDA CUBIST PHARMS
Jan. 8, 2019 PMDA MSD K.K.

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

None

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC J01DI54 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIBACTERIALS FOR SYSTEMIC USE
OTHER BETA-LACTAM ANTIBACTERIALS
Other cephalosporins and penems
MeSH PA D000900 Anti-Bacterial Agents
MeSH PA D000890 Anti-Infective Agents
MeSH PA D000892 Anti-Infective Agents, Urinary
MeSH PA D065093 beta-Lactamase Inhibitors
MeSH PA D004791 Enzyme Inhibitors
FDA CS M0003827 Cephalosporins
FDA EPC N0000175488 Cephalosporin Antibacterial
CHEBI has role CHEBI:33281 antibiotics
CHEBI has role CHEBI:35441 antiinfective agents

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Abscess of liver indication 27916005
Urinary tract infectious disease indication 68566005
Haemophilus influenzae pneumonia indication 70036007
Abdominal abscess indication 75100008
Cholecystitis indication 76581006 DOID:1949
Infectious disease of abdomen indication 128070006
Bacterial peritonitis indication 197171003
Bacterial cystitis indication 424551004
Sepsis caused by Haemophilus influenzae indication 447685007
Sepsis caused by Serratia indication 449084002
Bacterial pyelonephritis indication 838353009




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 2.97 acidic
pKa2 3.5 acidic
pKa3 11.54 acidic
pKa4 12.82 acidic
pKa5 13.65 acidic
pKa6 9.85 Basic
pKa7 4.05 Basic
pKa8 0.73 Basic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL ZERBAXA CUBIST PHARMS LLC N206829 Dec. 19, 2014 RX POWDER INTRAVENOUS 7129232 May 15, 2028 COMPLICATED INTRA-ABDOMINAL INFECTIONS (CIAI), USED IN COMBINATION WITH METRONIDAZOLE, IN ADULT AND PEDIATRIC PATIENTS (BIRTH TO LESS THAN 18 YEARS OF AGE)
EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL ZERBAXA CUBIST PHARMS LLC N206829 Dec. 19, 2014 RX POWDER INTRAVENOUS 7129232 May 15, 2028 COMPLICATED URINARY TRACT INFECTIONS (CUTI), INCLUDING PYELONEPHRITIS, IN ADULT AND PEDIATRIC PATIENTS (BIRTH TO LESS THAN 18 YEARS OLD)
EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL ZERBAXA CUBIST PHARMS LLC N206829 Dec. 19, 2014 RX POWDER INTRAVENOUS 7129232 May 15, 2028 METHODS FOR TREATING BACTERIAL INFECTIONS
EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL ZERBAXA CUBIST PHARMS LLC N206829 Dec. 19, 2014 RX POWDER INTRAVENOUS 7129232 May 15, 2028 METHODS OF TREATING BACTERIAL ILLNESSES
EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL ZERBAXA CUBIST PHARMS LLC N206829 Dec. 19, 2014 RX POWDER INTRAVENOUS 10028963 Sept. 7, 2032 TREATMENT OF HOSPITAL-ACQUIRED BACTERIAL PNEUMONIA
EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL ZERBAXA CUBIST PHARMS LLC N206829 Dec. 19, 2014 RX POWDER INTRAVENOUS 10028963 Sept. 7, 2032 TREATMENT OF VENTILATOR-ASSOCIATED BACTERIAL PNEUMONIA
EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL ZERBAXA CUBIST PHARMS LLC N206829 Dec. 19, 2014 RX POWDER INTRAVENOUS 9724353 Sept. 7, 2032 TREATMENT OF HOSPITAL-ACQUIRED BACTERIAL PNEUMONIA
EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL ZERBAXA CUBIST PHARMS LLC N206829 Dec. 19, 2014 RX POWDER INTRAVENOUS 9724353 Sept. 7, 2032 TREATMENT OF VENTILATOR-ASSOCIATED BACTERIAL PNEUMONIA
EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL ZERBAXA CUBIST PHARMS LLC N206829 Dec. 19, 2014 RX POWDER INTRAVENOUS 8685957 Sept. 27, 2032 METHODS OF TREATING BACTERIAL ILLNESSES
EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL ZERBAXA CUBIST PHARMS LLC N206829 Dec. 19, 2014 RX POWDER INTRAVENOUS 10420841 March 14, 2034 COMPLICATED INTRA-ABDOMINAL INFECTIONS (CIAI), USED IN COMBINATION WITH METRONIDAZOLE, IN ADULT AND PEDIATRIC PATIENTS (BIRTH TO LESS THAN 18 YEARS OF AGE)
EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL ZERBAXA CUBIST PHARMS LLC N206829 Dec. 19, 2014 RX POWDER INTRAVENOUS 10420841 March 14, 2034 COMPLICATED URINARY TRACT INFECTIONS (CUTI), INCLUDING PYELONEPHRITIS, IN ADULT AND PEDIATRIC PATIENTS (BIRTH TO LESS THAN 18 YEARS OLD)
EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL ZERBAXA CUBIST PHARMS LLC N206829 Dec. 19, 2014 RX POWDER INTRAVENOUS 10420841 March 14, 2034 TREATMENT OF COMPLICATED INTRA-ABDOMINAL INFECTION
EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL ZERBAXA CUBIST PHARMS LLC N206829 Dec. 19, 2014 RX POWDER INTRAVENOUS 10420841 March 14, 2034 TREATMENT OF COMPLICATED URINARY TRACT INFECTION
EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL ZERBAXA CUBIST PHARMS LLC N206829 Dec. 19, 2014 RX POWDER INTRAVENOUS 11278622 March 14, 2034 TREATMENT OF HOSPITAL-ACQUIRED BACTERIAL PNEUMONIA (HABP)
EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL ZERBAXA CUBIST PHARMS LLC N206829 Dec. 19, 2014 RX POWDER INTRAVENOUS 11278622 March 14, 2034 TREATMENT OF VENTILATOR-ASSOCIATED BACTERIAL PNEUMONIA (VABP)
EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL ZERBAXA CUBIST PHARMS LLC N206829 Dec. 19, 2014 RX POWDER INTRAVENOUS 8968753 March 14, 2034 COMPLICATED INTRA-ABDOMINAL INFECTIONS (CIAI), USED IN COMBINATION WITH METRONIDAZOLE, IN ADULT AND PEDIATRIC PATIENTS (BIRTH TO LESS THAN 18 YEARS OF AGE)
EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL ZERBAXA CUBIST PHARMS LLC N206829 Dec. 19, 2014 RX POWDER INTRAVENOUS 8968753 March 14, 2034 COMPLICATED URINARY TRACT INFECTIONS (CUTI), INCLUDING PYELONEPHRITIS, IN ADULT AND PEDIATRIC PATIENTS (BIRTH TO LESS THAN 18 YEARS OLD)
EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL ZERBAXA CUBIST PHARMS LLC N206829 Dec. 19, 2014 RX POWDER INTRAVENOUS 8968753 March 14, 2034 TREATMENT OF COMPLICATED INTRA-ABDOMINAL INFECTION
EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL ZERBAXA CUBIST PHARMS LLC N206829 Dec. 19, 2014 RX POWDER INTRAVENOUS 8968753 March 14, 2034 TREATMENT OF COMPLICATED URINARY TRACT INFECTION, INCLUDING PYELONEPHRITIS
EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL ZERBAXA CUBIST PHARMS LLC N206829 Dec. 19, 2014 RX POWDER INTRAVENOUS 10376496 Sept. 9, 2034 TREATMENT OF COMPLICATED INTRA-ABDOMINAL INFECTION IN PATIENTS WITH END-STAGE RENAL DISEASE ON HEMODIALYSIS
EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL ZERBAXA CUBIST PHARMS LLC N206829 Dec. 19, 2014 RX POWDER INTRAVENOUS 10376496 Sept. 9, 2034 TREATMENT OF COMPLICATED URINARY TRACT INFECTION IN PATIENTS WITH END-STAGE RENAL DISEASE ON HEMODIALYSIS
EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL ZERBAXA CUBIST PHARMS LLC N206829 Dec. 19, 2014 RX POWDER INTRAVENOUS 10933053 Sept. 9, 2034 TREATMENT OF HOSPITAL-ACQUIRED BACTERIAL PNEUMONIA IN PATIENTS WITH END-STAGE RENAL DISEASE ON HEMODIALYSIS
EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL ZERBAXA CUBIST PHARMS LLC N206829 Dec. 19, 2014 RX POWDER INTRAVENOUS 10933053 Sept. 9, 2034 TREATMENT OF VENTILATOR-ASSOCIATED BACTERIAL PNEUMONIA IN PATIENTS WITH END-STAGE RENAL DISEASE ON HEMODIALYSIS

Orange Book exclusivity data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRouteExclusivity dateDescription
EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL ZERBAXA CUBIST PHARMS LLC N206829 Dec. 19, 2014 RX POWDER INTRAVENOUS Dec. 19, 2019 NEW CHEMICAL ENTITY
EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL ZERBAXA CUBIST PHARMS LLC N206829 Dec. 19, 2014 RX POWDER INTRAVENOUS Dec. 19, 2024 GENERATING ANTIBIOTIC INCENTIVES NOW
EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL ZERBAXA CUBIST PHARMS LLC N206829 Dec. 19, 2014 RX POWDER INTRAVENOUS April 21, 2025 NEW PATIENT POPULATION

Bioactivity Summary:

None

External reference:

IDSource
37A4IES95Q UNII
D10097 KEGG_DRUG
4034036 VUID
N0000191292 NUI
936111-69-2 SECONDARY_CAS_RN
4034035 VANDF
4034036 VANDF
C3852726 UMLSCUI
CHEBI:134719 CHEBI
CHEMBL2103872 ChEMBL_ID
53234134 PUBCHEM_CID
DB09050 DRUGBANK_ID
CHEMBL1213250 ChEMBL_ID
9426 INN_ID
C519491 MESH_SUPPLEMENTAL_RECORD_UI
C000594038 MESH_SUPPLEMENTAL_RECORD_UI
10788 IUPHAR_LIGAND_ID
1597608 RXNORM
231579 MMSL
30783 MMSL
d08325 MMSL
015822 NDDF
015823 NDDF
708792003 SNOMEDCT_US
734470005 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
ZERBAXA HUMAN PRESCRIPTION DRUG LABEL 2 67919-030 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 1 g INTRAVENOUS NDA 28 sections
ZERBAXA HUMAN PRESCRIPTION DRUG LABEL 2 67919-030 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 1 g INTRAVENOUS NDA 28 sections